$4.22+0.20 (+4.98%)
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments.
Whitehawk Therapeutics, Inc. in the Healthcare sector is trading at $4.22. Wall Street consensus targets $6.50 (4 analysts), implying a +54.0% move over the next 12 months. The stock is currently 23% below its 52-week high of $5.50, remaining 44.0% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The ...
Ocular Therapeutix delivers FDA-approved eye therapies and devices, supported by a pipeline targeting multiple ocular diseases.
Whitehawk said it has secured rights from Hangzhou DAC to use the CPT113 linker-payload technology in up to five additional internally developed programs.
This San Diego biotech develops targeted therapies for RAS/MAPK-driven cancers, advancing several clinical candidates in oncology.
The market remained flat over the last week but is up 25% over the past year, with earnings forecast to grow by 17% annually. In light of these conditions, identifying stocks with strong financials and clear growth potential becomes crucial for investors seeking value. Although the term "penny stocks" may seem outdated, it still points to smaller or less-established companies that can offer significant opportunities; we've identified three such stocks that stand out for their financial...
Gainers Quantum Cyber (NASDAQ:QUCY) shares rose 163.0% to $0.85 during Wednesday's regular session. The market value of their outstanding shares is at $4.0 million. Whitehawk Therapeutics (NASDAQ:WHWK) stock moved upwards by 29.59% to $5.08. The company's market cap stands at $193.8 million. As per the news, the Q1 earnings report came out 4 days ago. Replimune Group (NASDAQ:REPL) stock moved upwards by 29.09% to $5.28. The market value of their outstanding shares is at $320.8 million. MaxCyte (